Vector
Rocky Mountain Spotted Fever
search
Rocky Mountain Spotted Fever
, Rickettsia rickettsii
See Also
Tick-Borne Disease
Vector Borne Disease
Prevention of Tick-borne Infection
Tick Removal
Epidemiology
Rocky Mountain Spotted Fever is the most common
Rickettsial Disease
in the United States
Up to 6000 cases per year of RMSF and related
Rickettsia
l spotted fevers (see below)
RMSF is the most lethal of
Tick Borne Illness
es (5-10% mortality)
Bimodal age distribution
Ages 5 to 9 years old (highest mortality)
Age over 40-60 years old
Timing
Most common
Apri
l to September (90% of cases)
Endemic area (only occurs in Western Hemisphere)
Central America
South America
North America
Occurs in all states except Maine, Hawaii, Alaska
Midwest
Atlantic coast and south central states (account for 60% of cases in U.S.)
North Carolina
Oklahoma
Arkansas
Tennessee
Missouri
Other similar
Rickettsia
l spotted fevers
Respond to similar
Antibiotic
s as those used in Rocky Mountain Spotted Fever
In U.S.
Rickettsia
l Pox (R. akari in North America)
American Boutonneuse fever (R. parkeri in southeast U.S.)
Finders Island Spotted
Fever
(R. honei in northwest U.S. as well as Australia and southeast Asia)
Non-U.S.
Mediterranean Spotted
Fever
or Boutonneuse
Fever
(R. connori in the Mediterranean)
Queensland Tick
Typhus
(R. australis in australia)
African
Tick Bite
Fever
(R. africae in africa)
Siberian Tick
Typhus
(R. sibirica in China)
Pathophysiology
Transmission
Tick to human transmission
Transmission may occur as early as 2 hours after
Tick Bite
Tick engorgement need not be present for transmission to have occurred
Person to person transmission does not occur
Tick Bite
(Ixodidae tick)
Wood tick (Dermacentor andersoni) is vector in Western U.S.
Dog tick (Dermacentor variabilis) is vector in Southern and Eastern U.S.
Other ticks transmitting spotted fever group
Bacteria
Rhipicephalus
Amblyomma
Macula
tum (Gulf Coast Tick)
Rickettsia rickettsii is causative organism
Gram Negative Bacteria
Small pleomorphic organism
Obligate intracellular
Parasite
Infects blood vessel walls
Infects endothelial cells and
Smooth Muscle Cell
s,
Spreads through
Lymphatic System
Secondary multiorgan
Small Vessel Vasculitis
ensues (especially involving skin and
Adrenal Gland
s)
Results in increased vascular permeability and decreased osmotic pressure
Presentation
Classic
Classic presentation in <18% of patients
Initial
Recent
Tick Bite
in endemic areas
Fever
and flu-like illness in spring and summer
Headache
Later (day 6)
Erythematous,
Macula
r rash (transitions to
Petechiae
)
Symptoms (follows 5-7 day incubation)
Fever
Frontal
Headache
Myalgias (back and leg
Muscle
s)
Malaise
Nausea
or
Vomiting
Abdominal Pain
(especially in children)
Signs
Rash (occurs in 90-95% of patients)
Onset in first week of illness (follows fever by 2-5 days)
Characteristics
Initial: Pink blanching
Macule
s 1 to 4 mm in diameter
Later:
Macule
s transition to
Papule
s and
Petechiae
(seen in 40-50% of patients)
Final: Coalesce into large
Ecchymoses
and ulcerations (eschar may form)
Distribution:
Centripetal Rash
- peripheral to central spread
Onset:
Wrist
s and ankles
Next: Spreads distally to palms and soles (may be only rash in as many as 40% of patients)
Next: Spreads proximally into upper arms and legs
Later: Trunk, axilla, buttocks, neck
Face is typically spared
Diagnosis
Missed diagnosis initially in up to 75% of cases
Delayed onset of rash until day 6 makes initial diagnosis more difficult
Start empiric management immediately on suspicion
Based on clinical findings
Do not rely on rash or
Thrombocytopenia
to make diagnosis
Specific testing is for confirmation only
Skin biopsy with immunofluorescent
Rickettsia
stain
Rickettsia
Serology
Differential Diagnosis
See
Purpura Causes
See
Febrile Eruption
See
Tick Borne Illness
Ehrlichiosis
Mycoplasma pneumonia
Syphilis
Lyme Disease
Coxsachievirus
Mononucleosis
Parvovirus B19
Kawasaki Disease
Leptospirosis
Roseola
Rubeola
Meningococcemia
Toxic Shock Syndrome
Scarlet Fever
Immune Thrombocytopenic Purpura
Labs
Complete Blood Count
White Blood Cell Count
normal or slightly decreased (
Leukopenia
)
Thrombocytopenia
Liver Function Test
abnormalities
Serum Bilirubin
increased (
Hyperbilirubinemia
)
Liver
transaminases increased
Aspartate Aminotransferase
(AST) increased
Alanine Aminotransferase
(ALT) increased
Renal Function
tests (
Serum Creatinine
and
Blood Urea Nitrogen
)
Acute Renal Failure
is a late finding
Serum Sodium
Hyponatremia
Cerebrospinal Fluid (indicated for associated neurologuc changes)
CSF
Pleocytosis
with monocytic predominance
Diagnosis
Skin
Punch Biopsy
with immunofluorescent stain for
Rickettsia
Used for confirmation, not for diagnosis
Test Sensitivity
: 60%
Test Specificity
: Very high
Rickettsia
Serology
Positive 7 to 10 days after symptom onset
Used for confirmation, not for diagnosis
IgG increases 4 fold from baseline when re-tested 2-4 weeks later
Management
Start empiric treatment immediately when diagnosis suspected
Do not delay treatment for diagnostic testing
Treatment delayed >5 days after onset increases mortality by 3 fold
Treatment is ideally started before rash onset (typically develops day 6)
Antibiotic
Course
Minimum course: 7 days
Continue
Antibiotic
s until afebrile for 3 days
Antibiotic
s
Doxycycline
for 7 days
Adult: 100 mg oral or IV twice daily
Child (<45 kg) 2.2 mg/kg (max 100 mg) twice daily
Children of any age and pregnant women should be treated with
Doxycycline
despite dental risks
Only effective treatment available for a condition with high risk for mortality
Chloramphenicol
(only if
Doxycycline
contraindicated)
Dose: 12.5 mg/kg orally four times daily for 7 days
Higher mortality than with
Doxycycline
Complications
Encephalitis
(and cerebral edema)
Noncardiac
Pulmonary Edema
and
Pulmonary Hemorrhage
Acute Respiratory Distress Syndrome
(
ARDS
)
Acute Renal Failure
Myocarditis
Cardiac Arrhythmia
Disseminated Intravascular Coagulation
Gastrointestinal Bleeding
Skin Necrosis
Prognosis
Untreated: 20-25% Mortality within 7 to 15 days (median 7 days)
Treated: 4-5% Mortality
Children have a higher mortality rate than adults
G6PD
is associated with complications and poor outcome
Prevention
See
Prevention of Vector-borne Infection
Resources
CDC Rocky Mountain Spotted Fever
http://www.cdc.gov/ncidod/dvrd/rmsf
References
(2016) Sanford Guide to
Antibiotic
s, IOS App accessed 4/14/2016
Chapman (2006) MMWR Recomm Rep 55(RR-4):1-27 [PubMed]
Cunha (2008) Lancet Infect Dis 8(3): 143-4 [PubMed]
Huntington (2016) Am Fam Physician 94(7): 551-7 [PubMed]
Pace (2020) Am Fam Physician 101(9): 530-40 [PubMed]
Thorner (1998) Clin Infect Dis 27:1353-60 [PubMed]
Type your search phrase here